Tristel PLC

LSE TSTL.L

Tristel PLC EBITDA for the year ending June 30, 2024: USD 12.66 M

Tristel PLC EBITDA is USD 12.66 M for the year ending June 30, 2024, a 27.25% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Tristel PLC EBITDA for the year ending June 30, 2023 was USD 9.95 M, a 83.49% change year over year.
Tristel PLC EBITDA for the year ending June 30, 2022 was USD 5.42 M, a -41.47% change year over year.
Tristel PLC EBITDA for the year ending June 30, 2021 was USD 9.27 M, a -19.61% change year over year.
Tristel PLC EBITDA for the year ending June 30, 2020 was USD 11.53 M, a 47.15% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

LSE: TSTL.L

Tristel PLC

CEO	Mr. Matthew G. Sassone
IPO Date	June 1, 2005
Location	United Kingdom
Headquarters	Lynx Business Park
Employees	250
Sector	Health Care
Industries Pharmaceuticals

Description

Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers medical instrument disinfection products, including airway management, cardiology, ear, nose and throat, endoscopy, gastrointestinal physiology, laboratory, ophthalmology, phlebotomy, reproductive health/IVF, surface, ultrasound, urology, women's health, and other products under the Tristel brand. Tristel plc was founded in 1993 and is headquartered in Snailwell, the United Kingdom.

Key trends

Past 5 years